For COVID, Consensus On Value Of Platform Trials, But A Confusion Of Consortia

 
• By Bridget Silverman

The coronavirus pandemic could be a turning point for master protocol and platform trial designs, but clear guidance and coordination are still needed.

Image of business partners hands on top of each other symbolizing companionship and unity
Master protocols are a cornerstone of the “critical path” for COVID-19 therapeutics proposed by a recent Duke-Margolis Center paper. • Source: Shutterstock

More from Clinical Trials

More from R&D